Diseases for which medicine offers few effective options-advanced cancer, neurogenerative diseases, lysosomal storage disorders and autoimmune diseases persist because they involve very complex and interrelated cellular operations. Bexion is committed to unlocking the workings of the lysosome, the key cellular orchestrator, to provide patients effective, non-toxic therapies where none currently exist. Our company founder and leadership team have deep experience across pharmaceutical operations, discovery, research and development, manufacturing, clinical, regulatory, and commercialization. The Bexion team is driven by the promise of developing life-changing therapies on our path to become a leading biotech company. Bexion has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Glioblastoma Multiforme (GBM) and Malignant Glioma including Diffuse Intrinsic Pontine Giloma (DIPG). To learn more about Bexion Pharmaceuticals, please visit Bexionpharma.com or contact Margaret M. van Gilse at (859) 446-7386 or mvangilse@bexionpharma.com